Dynamic in vivo binding of STAT5 to growth hormone-regulated genes in intact rat liver. Sex-specific binding at low- but not high-affinity STAT5 sites by Ekaterina V Laz et al.
Dynamic in Vivo Binding of STAT5 to Growth
Hormone-Regulated Genes in Intact Rat Liver.
Sex-Specific Binding at Low- But Not High-Affinity
STAT5 Sites
Ekaterina V. Laz, Aarathi Sugathan, and David J. Waxman
Division of Cell and Molecular Biology, Department of Biology, Boston University, Boston, Massachusetts 02215
Phylogenetic footprinting was used to predict functional transcription factor binding sites (TFBS) for
signal transducer and activator of transcription (STAT) 5, a GH-activated transcription factor, in the
GH-responsive genes IGF-I, SOCS2, and HNF6. Each gene, including upstream (100 kb) and downstream
regions (25 kb), was aligned across four species and searched for conserved STAT5-binding sites using
TFBS matrices. Predicted sites were classified as paired or single and whether or not they matched the
STAT5 consensus sequence TTCN3GAA. Fifty-seven of the predicted genomic regions were assayed by
chromatin immunoprecipitation from male rat liver with high STAT5 activity. STAT5 binding was
enriched (up to 24-fold) at eight genomic regions of IGF-I, including three novel regions in the second
intron, and at four regions of SOCS2, including three novel upstream sites. STAT5 binding to HNF6 was
modestly enriched (up to 3-fold) at one consensus site and two novel, nonconsensus sites. Overall, 14
of 17 identified sites were paired STAT5 sites. STAT5 binding to these sites was dynamic in male rat
liver, cycling on and off in response to each plasma GH pulse. Moreover, sex-specific STAT5 binding was
apparent; in female rat liver, where nuclear STAT5 activity is generally low, STAT5 binding to IGF-I and
SOCS2 was limited to high-affinity sites. Analysis of the verified STAT5 binding sites indicated that
STAT5 TFBS matrix 459 in combination with a STAT5 consensus sequence was the best predictor of
STAT5 binding to these three genes. Using these criteria, multiple novel STAT5 binding sites were
identified and then verified in several other GH-inducible genes, including MUP genes, where male-
specific gene expression was associated with male-specific STAT5 binding to multiple low-affinity
STAT5 sites. (Molecular Endocrinology 23: 1242–1254, 2009)
GH, a pituitary-secreted polypeptide hormone, regulates avariety of metabolic processes, including fatty acid oxida-
tion, amino acid uptake, and protein synthesis (1). The primary
targets of GH include liver, muscle, and adipose tissue. GH is
secreted from the pituitary in a sex-specific manner in rodents
and humans (2–5). In adult male rats, peaks of GH secretion
occur every 3–4 h and are separated by periods when GH is
virtually undetectable (episodic GH profile), whereas in adult
female rats, plasma GH peaks are more irregular and basal
hormone levels are elevated compared with males (continuous
GH profile) (2, 6). These sexually dimorphic plasma GH pro-
files establish and maintain sex differences in longitudinal bone
growth as well as sex differences in the expression of a large
number of genes in the liver (7–9).
GH binding to its cell surface receptor stimulates transphos-
phorylation of the GH receptor-associated Janus kinase 2
(JAK2) and activation of several downstream intracellular sig-
naling pathways (10–13), including those mediated by signal
transducer and activator of transcription (STAT) 5b. STAT5b is
a key transcriptional regulator of GH signaling in the liver (14–
18). STAT5b is activated by JAK2-dependent phosphorylation
of tyrosine residue 699, which enables STAT5b to dimerize and
translocate to the nucleus, where it binds DNA and activates
transcription of target genes (19). DNA response elements for
STAT5b and a closely related family member, STAT5a, collec-
tively referred to as STAT5, can be represented by the consensus
sequence TTCN3GAA (20). STAT5 is sensitive to the signal
dynamics of GH stimulation (pulsatile vs. near continuous) (21–
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23) and displays differential responsiveness to plasma GH stim-
ulation in male and female rat liver (24). In male rats, the pool of
liver STAT5 protein is repeatedly activated by each incoming
plasma GH pulse; thus, there is a strong positive correlation
between the plasma GH profile and the activity of STAT5 in the
liver, with STAT5 activity levels being high during the upswing
of a GH secretory episode and undetectable during the plasma
GH trough periods (25, 26). Female rats have substantially
lower liver STAT5 activity compared with male peak levels, but
their basal (interpeak) STAT5 activity, although low, is measur-
ably higher than the basal level in males (27).
IGF-I is a direct target of liver STAT5 (28–31). IGF-I medi-
ates the effects of GH on somatic growth and tissue maintenance
(1, 32, 33). The majority of circulating IGF-I is produced in the
liver, where GH induces its expression (34). Using chromatin
immunoprecipitation (ChIP), two DNA regions, each contain-
ing a pair of STAT5 binding sites, have been identified in the rat
IGF-I locus: region RE-1/RE-2, located 75 kb upstream of the
transcription start site, and region GHRE-1/GHRE-2, located in
the first intron (28, 31). STAT5 rapidly binds to these two re-
gions in liver after treatment of hypophysectomized rats with a
supraphysiological dose of GH, which induces transcription of
the IGF-I gene (28, 31). The two 5 distal STAT5 binding sites
(RE-1/RE-2) were also identified in the human IGF-I gene
through mapping of STAT5-binding enhancers (35). In addi-
tion, three novel IGF-I regions containing a total of five consen-
sus STAT5 binding sites were recently identified by ChIP anal-
ysis of GH-treated mouse liver (29).
STAT5 binding sites have been identified in liver for a limited
number of other GH-inducible genes. Suppressor of cytokine
signaling 2 (SOCS2) encodes a GH-inducible negative regulator
of JAK/STAT signaling that acts on GH receptor and other
cytokine receptor signaling pathways (36, 37). A GH-response
element containing a pair of STAT5 binding sites that is con-
served between rat and human SOCS2 was identified in the rat
(38). As shown by ChIP analysis, GH rapidly stimulates binding
of STAT5 to this region in the liver of hypophysectomized rats,
coincident with the induction of SOCS2 gene transcription (38).
Hepatocyte nuclear factor 6 (HNF6) may also be a direct target
of GH-activated STAT5 (39). HNF6 is a female-predominant
(40, 41), liver-enriched transcription factor that regulates the
transcription of a variety of genes (42–44), including certain
sex-dependent, GH-responsive CYP genes (40, 45, 46). A con-
sensus STAT5 binding site in the HNF6 promoter was shown to
bind STAT5 in a GH-dependent manner in vitro, and this
STAT5 binding site was required for GH-stimulated transcrip-
tion of an HNF6 promoter-reporter gene (39).
The known STAT5 binding sites in IGF-I, SOCS2, and
HNF6 were all identified under nonphysiological conditions,
i.e. in livers of hypophysectomized rats or mice given a supra-
physiological dose of GH or in vitro. Conceivably, additional
binding sites might be bound by STAT5 in liver in vivo, where
STAT5 binding to chromatin may vary during the course of a
naturally occurring plasma GH pulse in response to changes
in intranuclear concentrations of tyrosine-phosphorylated STAT5.
Furthermore, the extent to which STAT5 sites are occupied
might differ between males and females, due to the sex differ-
ences in plasma GH profiles. These and related issues are exam-
ined in the present study, where we use phylogenetic footprint-
ing to predict STAT5 binding sites in the IGF-I, SOCS2, and
HNF6 genes, and we test these sites experimentally by ChIP
analysis using livers of intact male and female rats. On the basis
of our findings, a refined computational approach is used to
predict, and then verify, liver STAT5 binding to several other
GH target genes, including MUP genes (47), which are ex-
pressed in a STAT5b-dependent and male-specific manner sub-
ject to GH regulation.
Results
Prediction and experimental evaluation of STAT5
binding sites for IGF-I, SOCS2, and HNF6
Table 1 presents a summary of STAT5 binding sites pre-
dicted in rat and three other species using a set of nine STAT5
transcription factor binding sites (TFBS) matrices (supplemental
Table S1, published as supplemental data on The Endocrine
Society’s Journals Online web site at http://mend.endojournals.
org). A majority (88%) of the predicted STAT5 sites fall into the
paired zero consensus and single nonconsensus categories, i.e.










Paired 2 consensus 2 2 2 2
Paired 1 consensus 32 12 10 5
Paired 0 consensus 207 25 11 1
Single consensus 18 4 3 2
Single nonconsensus 115 16 0 0
Total 374 59 26 10
SOCS2
Paired 2 consensus 2 1 2 2
Paired 1 consensus 11 1 1 1
Paired 0 consensus 135 13 8 0
Single consensus 12 2 3 1
Single nonconsensus 80 3 2 0
Total 240 20 16 4
HNF6
Paired 2 consensus 1 0 1 0
Paired 1 consensus 17 3 4 1
Paired 0 consensus 163 16 16 2
Single consensus 9 1 1 0
Single nonconsensus 91 9 0 0
Total 281 29 22 3
For experimental validation, preference was given to the sites conserved in all
four species (rat, mouse, human, and dog). Adjacent sites located in the
proximity of amplicons for other sites were in many cases not considered if not
found in all four species.
a STAT5 sites predicted for the rat genes based on a set of nine TFBS matrices
(see supplemental Table S1).
b Predicted rat STAT5 sites that are also present in mouse, human, and dog.
c Testing and verification is based on results for 57 amplicons (64 sites) presented
in Fig. 1 and data in Fig. 4.
Mol Endocrinol, August 2009, 23(8):1242–1254 mend.endojournals.org 1243
 at Boston Univ Libr Serials Dept - P35 on July 28, 2009 mend.endojournals.orgDownloaded from 
they do not contain the STAT5 binding site consensus sequence
TTCN3GAA. To test these STAT5 binding site predictions, we
primarily considered sites found in all four species because DNA
regulatory elements are often conserved evolutionarily (48, 49).
Predicted STAT5-binding sites were tested by ChIP followed by
qPCR (supplemental Table S2) using rat liver chromatin pre-
pared from an untreated male with high liver STAT5 activity
(see Fig. 2, sample 11). A total of 26, 16, and 22 predicted
STAT5 sites were tested in the IGF-I, SOCS2, and HNF6 genes,
respectively. Predicted STAT5-binding sites in close proximity
to each other [within 150 nucleotides (nt)] were considered to-
gether as part of a single STAT5 binding region. The chromo-
somal locations of the tested STAT5 binding sites and the cor-
responding amplicons used for experimental validation are
shown in supplemental Table S3. The abundance of STAT5
binding in the immunoprecipitated samples was normalized to
DNA input and compared with the abundance of signal for the
negative control, located within a 2300-nt segment in the 5
distal region of rat IGF-I that is devoid of any predicted STAT5
binding sites. Eight regions in the IGF-I gene (corresponding to
a total of 10 STAT5 sites) were enriched at least 2-fold over the
negative control in STAT5 antibody precipitates (Fig. 1A; sites
numbered in color). The highest enrichment (24-fold) was ob-
served for region 296, which contains three consensus STAT5
binding sites. Three of the eight regions are novel STAT5 bind-
ing regions, all located within intron 2 (regions 217, 232, and
260) (Table 2).
In the case of SOCS2, five regions were enriched more than
2-fold compared with the negative control (Fig. 1B). All five
regions (193, 199, 221/222, 224, and 225) are located 5 to the
rat SOCS2 gene. The weak ChIP signal of SOCS2 site 225 likely
comes from the adjacent strong STAT5 site 224, insofar as site
225 does not bind STAT5 in vitro (see below). Site 224 was
previously shown to bind STAT5 in the livers of hypophysecto-
mized rats treated with GH (38), whereas the other three sites
represent novel STAT5 binding regions. In the case of HNF6,
three STAT5-binding regions exhibited a 1.9- to 3-fold enrich-
ment over the negative control (Fig. 1C). HNF6 site 181 was
previously shown to bind STAT5 in a GH-dependent manner by
EMSA analysis (39), whereas the other two HNF6 sites, 148 and
157, are novel and contain paired nonconsensus STAT5 se-
quences (Table 2). The enrichment of STAT5 binding to these
regions of HNF6 is considerably lower than that for the stron-
gest STAT5 binding regions in the IGF-I and SOCS2 genes (Fig.
1). A fourth HNF6 region, 234, was approximately 2-fold en-
riched in STAT5 binding with respect to the IgG control but was
only 1.4-fold enriched relative to the negative control and was
not considered further.
Sex dependence of STAT5 binding in vivo
Liver samples from individual untreated male and female rats
were used in STAT5 ChIP analysis to investigate the relationship
between the temporal pattern of liver STAT5 activation (25, 26)
and STAT5 binding to chromatin. The STAT5 activity status of
each liver is shown in Fig. 2. STAT5 bands were quantified and
expressed as a percentage of the STAT5 signal in liver 11 (set at
100%). We assayed four males with high STAT5 activity (Fig. 2,
lanes 11–14, 60–100% of sample 11), four males with interme-
diate STAT5 activity (lanes 7–10, 3–34%), two males with no
detectable STAT5 activity (lane 6 and another, similar liver
sample, 0.2–0.3%). Four female livers, all having STAT5 activ-
ity that was very low but detectable were also assayed (lanes
1–4, 0.8–1.4% of sample 11; see intensified image at bottom for
detection of the low female liver signals). Samples were subject
to STAT5 ChIP analysis, with real-time PCR quantification of
each of the genomic regions enriched for STAT5 binding in Fig.
1. Clear differences in STAT5 binding were observed when com-
paring male liver samples with high vs. intermediate vs. very low
or undetectable STAT5 activity. The majority of STAT5 binding
regions were occupied in male samples with high STAT5 activity
(Fig. 3). These same regions exhibited lower STAT5 binding in
the intermediate STAT5 activity male group and no STAT5
binding, compared with the negative control, in the STAT5
activity-deficient male group. Because there is a strong positive
correlation between the plasma GH profile and liver STAT5
activity (25, 26), these results indicate that STAT5 cycles off of
its chromatin binding sites during the plasma GH interpulse
period. STAT5 binding at IGF-I region 260 and HNF6 regions
148 and 157, detected in the initial screen (Fig. 1C), was not
observed in Fig. 3 (2-fold enrichment relative to the negative
control), partially due to a lower sensitivity of the latter ChIP
experiment, where the cross-linked chromatin was not purified
and where 2- to 3-fold less DNA per ChIP sample was used
compared with the initial screening. STAT5 binding in female
liver samples, where STAT5 activity was marginally higher than
that of the STAT5-negative males (Fig. 2, lanes 1–4 vs. lanes 5
and 6) was indistinguishable from that of the STAT5-negative
males, except at IGF-I sites 196 and 304 and SOCS2 sites 224
(and 225) (Fig. 3). HNF6 bound STAT5 poorly compared with
the STAT5 binding sites in IGF-I and SOCS2, in agreement with
Fig. 1. Weak binding was observed at HNF6 region 181 in males
with high STAT5 activity levels but not in females or in other
males (Fig. 3B).
In vitro STAT5 binding to predicted sites
Although the above ChIP assays allowed us to identify in
vivo STAT5 binding regions, they have limited resolution and
do not establish whether a particular genomic sequence is capa-
ble of STAT5 binding. We therefore performed a competitive
EMSA assay to determine the intrinsic STAT5 binding activity
of the STAT5 sites enriched in the ChIP assay. As shown in Fig.
4 and summarized in Table 2, EMSA probes corresponding to
IGF-I sites 217, 296, 260, and 304; SOCS2 sites 193M, 199,
221 and 224; and HNF6 sites 148 and 181 all competed effi-
ciently for STAT5 binding. Less extensive competition was seen
with IGF-I sites 232 and 263 and HNF6 site 157. These findings
are consistent with these specific STAT5-binding sequences be-
ing responsible for the positive signals seen in the ChIP assay
(Fig. 1). IGF-I site 232 and HNF6 sites 148 and 157 correspond
to nonconsensus STAT5 binding sequences. Probes representing
SOCS2 sites 222 and 225 and the negative control probe Oct-1
did not compete for STAT5 binding. The inability of SOCS2 site
225 to compete for STAT5 binding supports our suggestion,
above, that its enrichment in ChIP reflects STAT5 binding to
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the adjacent site 224. Similarly, STAT5 binding to SOCS2
region 221/222 probably reflects STAT5 binding to site 221,
a strong binding site, and not to site 222.
Scatchard analysis of STAT5
binding affinity
We investigated the possibility that the
sites showing substantial STAT5 binding in
female liver (IGF-I sites 296 and 304 and
SOCS2 site 224; Fig. 3) have high affinity for
STAT5, which would enable them to bind
STAT5, both in males during a plasma GH
pulse, when STAT5 activity is high, and in
females, where STAT5 activity is low but
more persistent. EMSA assays revealed that
these three sites were the best competitors
for STAT5 binding among the probes tested
(Fig. 5A). Scatchard plot analysis revealed
that all three sites are high-affinity STAT5
binding sites, with dissociation constant
(Kd) values of approximately 1–2 nM (Fig.
5B). In contrast, SOCS2 site 199, which
shows high STAT5 binding in high STAT5
activity males but low STAT5 binding in fe-
males (Fig. 3B), is a low-affinity binding site,
Kd  9.3  0.7 nM (Fig. 5B), in agreement
with the rank order of STAT5 binding in
female liver in vivo.
Evaluation of STAT5 binding
site prediction
Overall, 17 of the 64 STAT5 sites tested
(27%) bound STAT5 in STAT5-positive
males (Fig. 1 and Table 1). In an effort to
improve the validation rate, we investigated
which features distinguish predicted sites
that bind STAT5 from those that do not.
This evaluation was based on the 64 STAT5
binding sites indicated in Fig. 1 plus 15 ad-
ditional sites that were conserved in fewer
than four species but were located in close
proximity to the 64 sites and therefore were
indistinguishable from them by ChIP. These
79 sites were classified according to 19 pos-
sible predictors of STAT5 binding (see Ma-
terials and Methods); these include the pres-
ence of a paired STAT5 site, a STAT5
consensus sequence in rat or in other species,
a STAT5 site predicted in one or more other
species, and a STAT5 site that is matched by
any of the nine available STAT5 matrices.
Measures of accuracy of prediction, sensitiv-
ity, specificity, positive predictive value
(PPV), negative predictive value (NPV), and
accuracy, were calculated for each predictor
(supplemental Table S5). The predictors
with the best combination of sensitivity and
specificity were found to be 1) the presence
of at least one consensus site in rat, and 2) a match with matrix
459. These two predictors also had the best accuracies and the
best combinations of PPV and NPV (Table 3). This finding is
FIG. 1. STAT5 binding regions identified by ChIP. Chromatin samples prepared from untreated male liver
with a high content of active STAT5 (sample 11 in Fig. 2) (35–60 g DNA per sample) were precipitated with
STAT5 antibody or normal rabbit IgG, and the abundance of STAT5 binding regions predicted in the IGF-I (A),
SOCS2 (B), or HNF6 (C) loci was quantified by real-time PCR. Data were normalized to input DNA and
expressed for each region as fold increase over the negative control (region within a 2300-bp segment in the
5 distal region of rat IGF-I, which is devoid of any predicted STAT5 binding sites). Data are mean  range
values for two independent determinations. qPCR primers used to assay each site are shown in supplemental
Table S2, and the chromosomal coordinates of the corresponding amplicons and predicted STAT5 sites are
shown in supplemental Table S3. In cases where predicted STAT5 sites were in close proximity, a single PCR
amplicon was used to interrogate both sites, as indicated (e.g. IGF-I sites 245 and 246, SOCS2 sites 221 and
222, etc.). Genomic locations of the sites positive for STAT5 binding are shown below each graph, as visualized
on the UCSC genome browser (http://genome.ucsc.edu). Red indicates sites present in all four species; green
indicates sites present in three of the four species considered. Numbers in parentheses indicate the number of
species (of four total) in which the local genomic region encompassing the site is at least 70% identical. All
STAT5 sites shown on the genome browser window except for IGF-I site GHRE-2, SOCS2 sites 193 and 221,
and HNF6 site 181 are present in all four species (rat, mouse, human, and dog).
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consistent with the fact that matrix 459 (supplemental Table S1) is
the only one of the nine STAT5 matrices that specifically describes
a binding site for STAT5b, the major liver STAT5 form (50, 51).
When the presence of a consensus STAT5 sequence and matrix 459
were combined as a single predictor, the specificity, accuracy, and
PPV all increased (Table 3). Applying the combined predictor to
the same three genes for sites conserved in at least three species
resulted in correct predictions for eight of 10 IGF-I sites, two of the
three SOCS2 sites, but not the one HNF6 site, with an overall
validation rate of 71%, as compared with about 27% in the orig-
inal analysis using all nine STAT5 matrices. Decreasing the mini-
mum number of species sharing a site to two resulted in the correct
prediction of all 14 validated consensus STAT5 sites and an overall
validation rate of 61% (supplemental Table S6). These two condi-
TABLE 2. Summary of STAT5 binding sites for rat genes enriched in ChIP assays







RE-1c Paired 1 consensus tctgtgttagtcaggaaaaTTCTAAGAAactgcctccagagagagg 24,458,482–24,458,527 Yes (Ref. 28)
RE-2c Single consensus tttTTCTTAGAAgta 24,458,733–24,458,747 Yes (Ref. 28)
GHRE-1c Paired 1 consensus ccgctcaccttgggggccTTCCTGGAAgaa 24,535,315–24,535,344 Yes
GHRE-2c Single consensus tgcTTCTTAGAAtga 24,535,399–24,535,413 Yes (Ref. 31)
217 Paired 2 consensus catTTCTTTGAAgtgcaaggagTTCCTGGAAcct 24,538,140–24,538,173 Yes
232 Paired 0 consensus ggatcccaagaaaaacccttcccttgc 24,544,749–24,544,775 Yes
260 Paired 1 consensus cattttaaacgtaagTTCTGAGAActg 24,557,417–24,557,443 Yes
263c Paired 1 consensus tctTTCAGGGAAatctaggaatatcagaaa 24,558,319–24,558,348 Yes




304c Paired 1 consensus tgaTTCCTAGAAaagatgacctcacccaac 24,580,690–24,580,719 Yes
SOCS2 on Chr7()





199 Paired 1 consensus tgcTTCTCAGAAtccgatgactaagccaggaatag 32,620,436–32,620,470 Yes
221 Single consensus agaTTCCAAGAAaac 32,611,389–32,611,403 Yes
222 Paired 0 consensus tagaattttctaaagagaaaaaaattactgcggataa 32,611,262–32,611,298 No








148 Paired 0 consensus tgatacccagaattctattgaccatgg 79,632,576–79,632,602 Yes
157 Paired 0 consensus tttccatcattaatgtcattactacgaacta(10)
tgtcgttgggagccgagtttcacggtattg
79,636,722–79,636,792 Yes
181c Paired 1 consensus gagccgggggcagcaggaTTCTAAGAAaga 79,644,216–79,644,245 Yes
RGS3 on Chr5()
113 Paired 1 consensus ttgtgtgctcagaccataTTCTCAGAAtaa 79,706,585–79,706,614 ND




12 (2c) Paired 1 consensus gatTTCTGGGAAcatggactcatagtccct 128,461,625–128,461,654 ND
21 (2b) Paired 0 consensus attgtcccagaaatccacttcctctcagatcctcagaaatg 128,378,512–128,378,552 ND
26 (2a) Paired 1 consensus tgatTTCTCAGAAcatggattagtagaagcg 128,436,433–128,436,463 ND
54 (2b) Paired 1 consensus cgcttctactaatccatgTTCTGAGAAatca 128,386,919–128,386,949 ND
MUPs on Chr5()
8 (OBP3) Single consensus gtcTTCTGAGAAtcc 78,179,829–78,179,843 Yes
9 (OBP3) Single consensus caaTTCATGGAAatt 78,179,664–78,179,678 Yes
29 Single consensus Various Various (see
supplemental Table S3)
Yes
50 Single consensus gtcTTCTGAGAAtcc Various (see
supplemental Table S3)
Yes
Chr, Chromosome. ND, not determined.
a Classification and chromosomal location of STAT5 binding sites are based on predictions made with all nine STAT5 TFBS matrices. The nt numbering is based on rat
genome assembly rn4.
b Consensus STAT5 binding sequence (TTCNNNGAA) within a predicted STAT5 binding site is shown in uppercase letters. Numbers in parentheses indicate the
nucleotide length of the intervening sequence that is not recognized by a STAT5 binding matrix.
c STAT5 binding sites identified in the present study that were also previously identified (Refs. 28, 29, 31, 35, 38, and 39).
d Number in parentheses indicates the SPIN2 gene located closest to the STAT5 binding site shown.
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tions can therefore be used to shortlist the predicted STAT5 can-
didate sites for experimental validation.
Genes that do not exhibit a pattern of expression similar to
that of IGF-I and SOCS2 may contain STAT5 binding sites that
do not match the STAT5 consensus sequence. Because matrix
459 is one of the best individual predictors (supplemental Table
S5 and Fig. S1), it can be applied on its own to predict noncon-
sensus as well as consensus sites. However, this would bias
results toward sites that resemble matrix 459, and it might be
more desirable to predict nonconsensus binding sites that are
closer to one of the other STAT5 matrices but with a more
stringent TFBS matrix matching (Possum) score. A Possum
score of at least 7, instead of the default value of 5, is not one of
the best predictors when applied alone (supplemental Table S5);
however, when applied as a second filter after selecting sites
that are found in all four species, a Possum score of 7 gives
results similar to those obtained using matrix 459; both pre-
dictors miss one verified site each, although the former pre-
dicts more unverified sites (supplemental Table S7).
Identification of STAT5 binding sites in other GH-
responsive genes
Two of the conditions considered above, presence of a
STAT5 consensus site and a match with matrix 459, were used
to predict STAT5 binding sites in a set of 12 early GH-respon-
sive genes, previously identified in rat liver by microarray anal-
ysis (CALD1, GADD45G, NREP, SULT2A1, RGS3, SPIN2A,
SPIN2B, and five members of the MUP gene family) (52). These
genes are all down-regulated in hypophysectomized compared
with intact male rat liver and are rapidly induced (within 30–90
min) by a single, physiological GH injection, making them can-
didates for direct STAT5 target genes (supplemental Table S8).
ChIP analysis revealed strong STAT5 binding to two sites in
RGS3 (sites 113 and 122) and to four sites in the SPIN2 genes
(Fig. 6A, sites 12, 21, 26, and 54) (Table 2). Multiple functional
STAT5 binding sites were found for the MUP genes (sites 8/9,
site 29, and site 50, Fig. 6B). The amplicons representing sites 29
and 50 each mapped to six distinct genomic sequences associ-
ated with the eight known MUP genes (Fig. 6B) and thus could
not be assigned to a specific MUP gene; most likely, multiple
MUP region genomic positions contribute to the observed site
29 and site 50 ChIP signals. In the case of MUP sites 8/9, which
are conserved in at least three MUP genes (OBP3, MUP4, and
LOC259246), a gene-specific amplicon [designated 8/9 (OBP3)]
could be designed. STAT5 binding to all of the active MUP
binding regions was male specific in liver chromatin (Fig. 6C),
consistent with the strong male specificity of MUP gene expres-
sion in rat liver (47, 52, 53). Scatchard plot analysis for binding
of STAT5 to OBP3 sites 8 and 9 (whose local sequences are also
shared by sites 29 and 50 of OBP3, LOC259246, and several
other MUP genes; supplemental Table S9) yielded Kd values of
approximately 10–12 nM (Fig. 6D). The low affinity of these
male-specific STAT5 sites further supports the hypothesis that
STAT5 binding in females primarily occurs at high-affinity
sites. None of the predicted STAT5 sites tested for CALD1
(four sites), GADD45G (two sites), NREP (one site), or
SULT2A1 (one site) bound STAT5 in liver chromatin (data not
shown).
Discussion
STAT5b is an essential mediator of GH action in the liver, where
it regulates the transcription of many genes either directly or
indirectly. In rat liver, at least 20% of the genes acutely stimu-
lated by GH and a majority of the genes acutely suppressed by
GH are dependent on STAT5b for their regulation (38, 54). This
study investigated the utility of phylogenetic footprinting for
discovery of STAT5 binding sites in GH-responsive genes. In
addition, the dynamic effect of plasma GH profiles on STAT5
binding to chromatin was investigated in intact male and female
rat liver. We used a computational approach to predict STAT5
binding sites, where sequences associated with each gene and its
flanking DNA (100 kb upstream sequence and up to 25 kb
downstream sequence) were first scanned using TFBS matrices
for STAT5. Long genomic sequences were analyzed because of
the emerging evidence that STAT5 often binds to genes outside
of the traditional promoter region (28, 29, 55). Unlike previous
studies, where only the consensus sequence TTCN3GAA was
considered in predicting STAT5 binding sites (29, 38, 55), our
approach used TFBS matrices, including matrices based on non-
consensus STAT5 sequences (56). The relevance of nonconsen-
sus sequences is supported by a recent identification of a STAT5
binding region containing multiple nonconsensus sequences in
the promoter of C3ar1 (57). Because regulatory elements are
often conserved between species (48, 49), predicted rat STAT5
sites that were conserved across the other three species exam-
ined (mouse, human, and dog) were given preference for exper-
imental verification. Moreover, in contrast to previous studies,
where STAT5 binding sites associated with IGF-I, SOCS2, and
HNF6 were identified either under nonphysiological conditions
or in vitro (28, 29, 31, 38, 39), we evaluated STAT5 binding in
intact, untreated male rats, and we tested the hypothesis that
STAT5 binding to chromatin in liver in vivo is dynamically
FIG. 2. EMSA analysis of STAT5 DNA-binding activity in individual adult rat
livers. Homogenates prepared from individual rat livers were assayed for STAT5
binding using a 32P-labeled STAT5 binding probe (STAT5 response element of
the rat -casein promoter; supplemental Table S4). Male livers were classified as
high () (lanes 11–14), intermediate () (lanes 7–10), and no STAT5 activity
() (lanes 5 and 6). Male liver 11 was used in ChIP experiments presented in Fig.
1 and was included with the other livers in ChIP experiments presented in Fig. 3.
EMSA band intensities expressed as a percentage of liver 11 are shown above
each lane. All 14 lanes were from the same gel and exposure. Lower panel
shows lanes 1–6 at a higher intensity to better visualize the differences in STAT5
activity content between female samples (first four lanes) and STAT5 () male
liver samples (last two lanes). All samples shown, except for liver 5, were used for
the ChIP analyses shown in Fig. 3.
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responsive to plasma GH pulsation. ChIP analysis performed
with chromatin prepared from livers of male rats killed at the
time of a plasma GH pulse, when liver nuclear STAT5 activity is
high, enabled us to identify multiple STAT5 binding regions in
each gene (Table 2). Multiple STAT5 binding regions were re-
ported previously for IGF-I in mouse liver (29), but only one
STAT5 region was previously identified for SOCS2 (38) and for
HNF6 (39). Thus, these three genes, as well as several other
GH-responsive genes examined here (Fig. 6), all
contain multiple STAT5 binding sites. Notably, all
of the STAT5 sites identified previously for IGF-I,
SOCS2, and HNF6 under nonphysiological condi-
tions or in vitro were found to bind STAT5 in male
liver in vivo.
The majority of the STAT5 binding sites identi-
fied in this study were paired sites, containing either
one or two consensus STAT5 sequences (Table 2).
STAT5 may bind to these sites in tandem, as tetram-
ers, which can be expected to bind with a high over-
all binding affinity. In vitro binding studies demon-
strate, however, that STAT5b, which is the major
(90%) STAT5 form in liver (50, 51), is less likely
to form tetramers on DNA than STAT5a (56, 58).
Nevertheless, two of the strongest binding sites for
liver STAT5 (IGF-I site 296 and SOCS2 site 224)
contain either three (site 296) or two (site 224)
STAT5 consensus sequences, raising the possibility
that these sites may show enrichment for STAT5a.
The tandem location of two consensus STAT5 sites
served as a good predictor of STAT5 binding in the
case of IGF-I and SOCS2. For HNF6, however, this
prediction failed; its paired two-consensus sequence
at site 12 (supplemental Table S3) did not bind
STAT5. In the case of RGS3, SPIN2A and SPIN2B,
which are rapidly induced by a physiological pulse of
GH in rat liver (supplemental Table S8) (52), the
STAT5 sites identified were all paired sites. STAT5
binding sites associated with MUP genes, on the other
hand, were single consensus sites (Table 2).
The highest predictive score was achieved when
STAT5 site predictions were based on a combina-
tion of two criteria: 1) presence of a consensus
STAT5 binding sequence and 2) recognition by
STAT5 matrix 459. Together, these criteria pre-
dicted all of the IGF-I, SOCS2, and HNF6 STAT5
binding sites identified here, with the exception of
nonconsensus STAT5 sites, which would necessar-
ily be missed using this approach. Multiple STAT5
sites in RGS3 and in various SPIN2 and MUP genes
were also correctly predicted. Three of the noncon-
sensus sites enriched by STAT5 ChIP competed for
STAT5 binding in vitro (HNF6 sites 148 and 157
and IGF-I site 232), supporting the conclusion that
these sites bind STAT5 in vivo. Two other noncon-
sensus sites that gave ChIP signals did not compete
for STAT5 binding in vitro (SOCS2 sites 222 and
225), suggesting that the ChIP enrichment in these
genomic regions reflects STAT5 binding to neighboring sites.
Because the evaluation of predictors was primarily based on
ChIP data obtained for IGF-I and SOCS2, the above two pre-
dictors can be best applied to genes that are similar to IGF-I and
SOCS2, i.e. genes that respond rapidly and strongly to GH, and
in a sex-independent manner. Such genes are likely to contain
high-affinity STAT5 binding sites that match the consensus se-
quence. Genes characterized by other patterns of GH respon-
FIG. 3. ChIP analysis of STAT5 binding in female liver and in male livers that differ in STAT5
activity content. STAT5 binding to the indicated regions in IGF-I (A), SOCS2 (B), and HNF6 (B)
were analyzed by ChIP using the indicated sets of male and female chromatin samples, prepared
from individual untreated livers of adult female rats or from adult male rats with high (),
intermediate () and no () liver STAT5 activity, as indicated in Fig. 2 (20–25 g DNA per
sample). The ChIP enrichment at each STAT5 binding region was quantified and expressed as
described in Fig. 1. Data shown are mean  SEM for each group [n  2 livers for STAT5 () male
group and n  4 livers for the other three groups]. STAT5 binding to IGF-I sites 296 and 304 and
to SOCS2 site 224 (and 225) in female liver chromatin was substantially higher than in the
STAT5 () male samples, despite the very small difference in STAT5 activity content (cf. Fig. 2).
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siveness may contain weaker, noncanonical binding sites. To
predict such nonconsensus sites, a better strategy might be to first
filter sites that are found in all four species and then select sites that
are predicted by matrix 459 or by any of the other eight matrices
but with a higher (more stringent) Possum score.
The three verified HNF6 STAT5 binding regions identified
here correspond to 14% of the sites tested, as compared with 38
and 25% of the sites tested for IGF-I and SOCS2, respectively.
STAT5 binding at all three HNF6 regions was weak in compar-
ison with the strong STAT5 binding regions associated with
IGF-I and SOCS2. Moreover, STAT5 binding at HNF6 region
181, which gave the strongest HNF6 STAT5 binding signal, was
conserved in only three of the four species (absent in mouse), in
contrast to the conservation of the strongest binding regions of
IGF-I and SOCS2 across all four species. Conceivably, HNF6,
whose expression is approximately 3-fold higher in female than
in male liver (40, 41), may be regulated by other, stronger
STAT5 binding sites that were not identified here. These could
include STAT5 sites not conserved across species, in view of
the fact that site 181 was not conserved in the mouse yet was
the strongest of the three HNF6 sites identified. In addition,
GH may in part regulate HNF6 via STAT5-independent
mechanisms.
Comparison of STAT5 binding in livers of male rats with
different levels of STAT5 activity revealed a direct relation-
ship between STAT5 binding to chromatin and the STAT5
activity content of the livers. Because STAT5 activity in male
liver exhibits a very strong positive correlation with the oc-
currence of a pulse in the plasma GH profile (25, 26), these
findings indicate that STAT5 binding to liver chromatin is
FIG. 4. In vitro STAT5 binding determined by competitive EMSA analysis of
predicted STAT5 sites. STAT5-positive male rat liver extract was incubated with
32P-labeled double-stranded STAT5 binding probe from the -casein promoter
and a 100-fold molar excess of unlabeled oligonucleotide corresponding to each
of the indicated STAT5 binding sites (supplemental Table S4). In cases where the
predicted STAT5 binding region (Table 2 and supplemental Table S3) was long
and contained a nonbinding sequence in the middle, two oligonucleotide probes
(designated L and R) were synthesized to assay STAT5 binding to sequences to
the left and to the right, respectively, of the intervening sequence. Probes for site
193 represented the middle (193M) or the right (193R) portion of the full
sequence containing two extended nonbinding intervening sequences. Oct-1
served as a non-STAT5 binding (control) DNA sequence. STAT5-binding regions
GHRE-2, RE-1, and RE-2 of IGF-I were shown previously to bind to rat STAT5 in
vitro (28, 31) and were not included in these analyses. Numbers above each lane
indicate the STAT5 site being tested, and numbers below each lane represent the
intensity of the STAT5-DNA band (marked with an arrow) relative to its
intensity in the absence of an unlabeled competitor (the first lane of each gel,
none, 100%).
FIG. 5. Analysis of STAT5 binding affinity. A, The ability of predicted STAT5
binding sites to compete for binding to STAT5 in vitro was tested by EMSA as
described in Fig. 4 but using 10-, 30-, and 100-fold molar excess of unlabeled
competing oligonucleotides representing the indicated predicted STAT5 binding
sites of IGF-I and SOCS2. Each bar represents the intensity of the STAT5-DNA
band in the presence of the competing oligonucleotide expressed as percentage
of the signal in the absence of a competing probe (set at 100%). Numbers below
the bars indicate the STAT5 site being tested. Oct-1 is the non-STAT5 binding
(control) DNA sequence. For each gene, probes are ordered based on increasing
competitive binding activity. B, Kd values for binding of STAT5 to four STAT5
binding sites (sites 296 and 304 of IGF-I and sites 199 and 224 of SOCS2) were
determined by Scatchard plot analysis of EMSA data. Nuclear extract prepared
from GH-stimulated 293T cells transfected with rat GH receptor and rat STAT5b
expression plasmids was incubated in the presence of 0.25 nM 32P-labeled
double-stranded oligonucleotides for sites 296, 304, 199, or 224 and increasing
amounts of the same but unlabeled probe. The intensity of the STAT5-DNA band
and the free probe on the gel was quantified, and the results were plotted. Kd
values shown are mean  SEM values for two to five independent determinations
calculated from the negative inverse of the Scatchard plot slopes. Shown in B are
representative experiments for each probe. For IGF-I site 296, a truncated
oligonucleotide probe (296R) representing part of the predicted sequence for this
site and containing two of the three consensus STAT5 binding sequences was
used in the assay in A, whereas a full-length DNA probe containing all three
consensus STAT5 binding sequences of site 296 was used for the Kd
determination (B).
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dynamic; i.e. it is directly induced by GH and cycles on and
off chromatin in response to each plasma GH pulse. In males,
STAT5 binding to these sites during a plasma GH pulse
[STAT5 () livers; Figs. 2 and 3] is followed by a near-
complete loss of STAT5 binding between GH pulses [STAT5
() livers]. Few of the STAT5 binding regions of IGF-I and
SOCS2 that were occupied in high STAT5 activity male liver
were also occupied in female liver, and in the case of the MUP
genes, none was detectably occupied in females. These latter
sites may contribute to GH regulation of the MUP genes,
whose expression is highly male specific and is, in part,
STAT5 dependent (14, 59).
The three regions of IGF-I and SOCS2 that bound STAT5 in
female liver were among the strongest binding regions in males
(IGF-I sites 296 and 304 and SOCS2 site 224). Given the low
STAT5 activity that is generally found in female rat liver (Fig. 2)
(26), STAT5 activity may simply be too low for STAT5 to bind
at the other sites in female liver. Indeed, IGF-I sites 296 and 304
and SOCS2 site 224 are presently shown to be high-affinity
binding sites (Kd 1–2 nM), whereas SOCS2 site 199, where
STAT5 binding was observed only in males, is a low-affinity
site (Kd 9 nM). This finding indicates that sex-specific
STAT5 binding, e.g. linked to the expression of sex-specific
genes, is more likely to occur at low-affinity STAT5 sites than
at high-affinity sites. This hypothesis is further supported by
our finding that the male-specific STAT5 binding sites in
MUP genes bind STAT5 with low affinity (Fig. 6D). Other
factors, such as differences in chromatin structure or the pres-
ence or absence of proteins that modulate STAT5 binding to
DNA, could also contribute to the sex differences in STAT5
binding seen at some sites. Given our finding that a majority
of the STAT5 binding sites in IGF-I and SOCS2 bound
STAT5 in a male-specific manner, an important question is
whether all of these sites contribute to gene transcription in
liver in vivo, insofar as these two genes do not show sex
dependence (supplemental Table S8). Conceivably, IGF-I
and SOCS2 transcription could be primarily regulated by
STAT5 binding to sites that show high STAT5 binding in
both male and female liver, i.e. the high-affinity sites. Al-
though the occupancy of those sites by STAT5 in female liver
is somewhat lower than in males, it is presumably more per-
sistent due to the persistence of low-level GH signaling to
STAT5 in females (27). Additional experiments will be re-
quired to address these questions.
Materials and Methods
Prediction of STAT5 binding sites
A computational phylogenetic footprinting method was developed
to predict the occurrence of STAT5 binding sites that are conserved
across the rat (rn4), mouse (mm8), human (hg18), and dog (canFam2)
genomes for the IGF-I, SOCS2, and HNF6 genes. Sequences encom-
passing 100 kb of the upstream region, the full coding sequence region,
including all exons and introns, and either 3 kb (IGF-I and SOCS2) or
25 kb (HNF6) downstream of the coding sequence, were first scanned
individually for each species for the occurrence of STAT5 binding sites,
i.e. genomic sequences that match position weight matrices that describe
a binding site for STAT5. A total of nine position weight matrices were
used, five of which were obtained from the TRANSFAC database (60).
One of the TRANSFAC matrices, derived from a study of STAT5 bind-
ing to synthetic oligonucleotides (56), includes sequences that contain a
STAT5 consensus site as well as sequences that bind STAT5 but do not
match the STAT5 consensus sequence TTCN3GAA. To better detect
nonconsensus STAT5 binding sites, this matrix was separated into two:
one for paired STAT5 binding sites with one consensus sequence
(M00AS01) and another for paired sites with no consensus sequence
(M00AS02). Two other matrices were generated from a set of published
STAT5 binding sequences (56) that were not represented in any of the
TRANSFAC STAT5 matrices: one for paired STAT5 binding sites with
a 7-bp spacer sequence (M00AS03) and another for paired STAT5 bind-
ing sites that were weak binders (M00AS04). The nine STAT5 matrices
used in this study are provided in supplemental Table S1.
The matrix scanning tool Possum (61) was used to find sites in each
genomic sequence that match one or more of the nine STAT5 matrices,
and all hits that met a Possum threshold score of 5 were stored. Se-
quences from the four species examined were then aligned to identify
hits that are conserved across species, which was accomplished as fol-
lows. Pairwise alignments were generated between the rat sequence and
each of the other three species using two different algorithms for rapid
global alignment, AVID (62) and LAGAN (63). The stand-alone version
of the program VISTA (64) was then used to identify conserved regions
in each pairwise alignment. Conserved regions were defined as segments
at least 100 nt in length that are at least 70% identical between the two
sequences. For each of the sites predicted in the rat sequence by Possum,
the best pairwise alignment with each of the other three species, ob-
tained from either AVID or LAGAN, was chosen. Sites that were shared
across all four species were considered to be most likely to be functional
in STAT5 binding. Each predicted STAT5 binding site was classified
according to whether it contains the consensus STAT5 binding sequence
TTCN3GAA in rat, which was used as the reference species. STAT5
binding sites were also classified as single or paired. A paired site was
defined as one that has an overall length that is greater than twice the
length of a single binding site for STAT5 (12 nt, including 3-nt flanking
sequence), with a maximum intervening sequence length of 50 nt. Pre-
dicted STAT5 sites less than 50 nt apart were concatenated and classi-
fied as paired sites. The above analysis was automated using a Perl
program, which is available upon request.
TABLE 3. Summary statistics for the two best individual predictors for STAT5 binding sites
Predictor(s) TP TN FP FN Sensitivitya Specificityb PPVc NPVd Accuracye
1 consensus site in rat 15 46 15 3 0.83 0.75 0.50 0.94 0.77
Matrix 459 17 45 16 1 0.94 0.74 0.52 0.98 0.78
Matrix 459 
consensus site
15 50 11 3 0.83 0.82 0.58 0.94 0.82
True positives (TP), true negatives (TN), false positives (FP), false negatives (FN), sensitivity, specificity, PPV, NPV, and accuracy (see definitions in Table footnotes) for the
two best individual predictors and the combination of the two are listed.
a Sensitivity  TP/(FN  TP); b Specificity  TN/(FP  TN); c PPV  TP/(TP  FP); d NPV  TN/(FN  TN); e Accuracy  (TP  TN)/(TP  TN  FP  FN).
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Chromatin cross-linking and DNA fragmentation
Two different methods were used to prepare cross-linked chromatin
from Fischer 344 rat liver. For the experiments shown in Fig. 1, a high
STAT5 activity adult male rat liver sample was used to screen the pre-
dicted STAT5 binding regions of IGF-I, SOCS2, and HNF6. Chromatin
was purified from freshly isolated liver nuclei that were immediately
cross-linked with formaldehyde using a procedure adapted from a
mouse liver protocol (65), followed by sonication, as detailed in supple-
mental Materials and Methods. For all other analyses, cross-linked sam-
ples were prepared from frozen livers excised from intact, untreated
adult male and female rats (12–13 wk old). Livers were stored at 80 C
and processed for cross-linking as described (31), with modifications,
followed by sonication, as detailed in supplemental Materials and Meth-
ods. All animal protocols were approved by the Boston University In-
stitutional Animal Care and Use Committee.
ChIP
All steps were performed at 4 C, unless indicated otherwise, using
cross-linked samples prepared as described above. Samples were pre-
pared from frozen liver and diluted into immunoprecipitation buffer [20
mM Tris-HCI (pH 8.1), 150 mM NaCl, 2 mM EDTA, 1% Triton X-100,
0.1% sodium dodecyl sulfate (SDS)] containing complete protease in-
hibitor cocktail, or were prepared from cross-linked nuclei and diluted
in RIPA buffer [50 mM Tris HCI (pH 8.1), 150 mM NaCl, 1% IGEPAL
CA-630, 0.5% sodium deoxycholate, 0.1% SDS] containing complete
protease inhibitor cocktail, as described in the supplemental Materials
and Methods. Samples were precleared for 1 hr with Protein A Sepha-
rose CL-4B beads (GE Healthcare, Piscataway, NJ) (50% slurry in im-
munoprecipitation buffer or RIPA buffer containing 1 mg/ml BSA and
200 g/ml salmon sperm DNA: 40 l slurry/ml of sample). Duplicate
50-l aliquots (input) were taken from each precleared sample, and the
remainder was divided into 0.9- to 1-ml aliquots. STATS antibody N-20
(sc-836 or sc-836X; Santa Cruz Biotechnology, Santa Cruz, CA) or
normal rabbit IgG (sc-2027; Santa Cruz) was added to duplicate or
triplicate aliquots (6 g IgG/aliquot) followed by incubation overnight.
After a 2-h incubation with protein A-Sepharose CL-4B beads (40 l
50% slurry per aliquot), the aliquots were washed twice with immuno-
precipitation or RIPA buffer (1 ml per wash per aliquot), twice with
immunoprecipitation or RIPA buffer containing 0.5 M NaCl, and twice
with TE buffer [10 mM Tris HCl (pH 8.1), 1 mM EDTA]. Extraction of
FIG. 6. STAT5-binding regions identified in RGS3, SPIN2, and MUP genes. Cross-linked chromatin samples prepared from frozen untreated male liver with high
content of active STAT5 (sample 12 in Fig. 2) were precipitated with STAT5-antibody or normal rabbit IgG, and the abundance of STAT5 binding regions predicted in
the RGS3 and SPIN2 (A) or MUP (B) loci was quantified by real-time PCR. Data were normalized and expressed as in Fig. 1 and shown as mean  range of two
determinations for each predicted STAT5 site. Text in parentheses in A indicates which of the three SPIN2 genes (SPIN2A, SPIN2B, and SPIN2C) this site is located closest
to. Text in parentheses in B indicates whether the STAT5 binding site was assayed for a single MUP gene (gene OBP3) or for several MUP genes together (MUP). ActB is
a region within the third intron of -actin that served as an additional negative control; this region is devoid of any predicted STAT5 binding sites, and -actin is not
regulated by GH. Genomic locations of the sites positive for STAT5 binding are shown below each graph, as in Fig. 1. Below A, numbers in parentheses indicate the
number of species (for RGS3 sites) or the number of genes (for SPIN2 sites) in which the local genomic region encompassing the site is at least 70% identical. The SPIN2
region STAT5 sites shown on the genome browser window are present in all three SPIN2 genes, except for SPIN2 site 12, which is found in SPIN2B only. Below B, the
MUP region RefSeq genes shown correspond to the eight known rat MUP genes; these are given various MUP, OBP, and LOC designations, as indicated. The STAT5-
positive MUP sites designated 29 and 50 were interrogated with generic MUP region primers; each amplicon amplifies genomic sequences associated with six distinct
sites, numbered 29A through 29F and 50A through 50F, as shown. Sites 8 and 9 are close, but distinct STAT5 sites that were interrogated by PCR primers mapping to
the specific genomic region as indicated. C, STAT5 binding to the indicated MUP region sites (see B) was analyzed by ChIP in the sets of male and female liver
chromatin samples prepared from individual untreated adult female rats and male rats with high liver STAT5 activity (samples shown in lanes 1–3 and 11–13,
respectively, in Fig. 2). The abundance of STAT5 binding regions was quantified and expressed as described in Fig. 1. Data are the mean  SEM for each group (n  3).
Dashed horizontal lines indicate ChIP activity of the negative control. D, Scatchard analysis of STAT5 binding to sites 8 and 9 of the OBP3 gene (n  2–3
determinations, mean  SEM, as in Fig. 5B). The sequences of these sites are identical to those of several other STAT5 binding sites predicted in various MUP genes, as
indicated in supplemental Table S9.
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DNA from the beads was performed as described (66). Briefly, 100 l
10% (wt/vol) Chelex 100 resin (Bio-Rad Laboratories, Hercules, CA) in
water was added to the washed protein A-Sepharose CL-4B beads and
the samples were boiled for 10 min to reverse cross-linking. After treat-
ment with 20 g proteinase K (Bioline, Taunton, MA) for 30–40 min at
56 C, the samples were boiled for 10 min, and supernatants (80 l) were
collected. Water (120 l) was added to the beads, the samples were
vortexed, and the supernatants were collected and pooled with the first
set of supernatants to give 200 l total supernatant volume. The samples
were stored at 20 or 80 C and used undiluted in quantitative real-
time PCR (qPCR) assays. Input samples (see above) were incubated for
6 h at 65 C in the presence of 0.2 M NaCl to reverse cross-linking,
followed by successive treatments with 5 g ribonuclease A (Novagen,
Gibbstown, NJ) for 30 min at 37 C (not performed for samples prepared
from cross-linked nuclei) and with 20 g proteinase K for 2 h at 56 C.
DNA was extracted with phenol/chloroform/isoamyl alcohol (25:24:1)
and precipitated overnight with ethanol in the presence of 10 g glyco-
gen (Ambion, Austin, TX) per input sample. The pellets were washed
with 95% ethanol, dissolved in 50 l water, and stored at 20 C. For
qPCR, the input samples were diluted 50 times in water containing 50
g/ml yeast RNA (Ambion).
Real-time PCR
Triplicate 5-l real-time PCR mixtures, each containing Power
SYBR Green PCR Master Mix (Applied Biosystems, Foster City, CA),
312 nM each qPCR primer, and 0.5–1.5 l DNA template were loaded
onto a 384-well plate and run through 40 cycles on an ABS 7900HT
sequence detection system (Applied Biosystems). Primer sequences and
the chromosomal positions of each amplicon are listed in supplemental
Tables S2 and S3, respectively. The results for each STAT5 binding
region for a given liver sample were derived from averages of duplicate
or triplicate immunoprecipitation samples. Data were normalized to
input and are presented as fold increase over negative control. For a
negative control, we used an amplicon centered within a 2300-bp seg-
ment in the 5 distal region of the rat IGF-I gene, which is devoid of any
predicted STAT5 binding sites (supplemental Table S3). Similar results
were obtained using a second negative control, from a STAT5 site-
deficient region of the rat -actin gene (supplemental Table S3). Data
obtained in ChIP analysis carried out using normal rabbit IgG in place of
STAT5 antibody N-20 corresponds to an additional control and is pre-
sented in Figs. 1 and 6 for each qPCR primer pair.
Preparation of liver homogenates and EMSA
Liver homogenates were prepared from frozen rat liver tissues as
described (27) by homogenizing pieces of liver on ice in homogeni-
zation buffer [10 mM Tris-Cl (pH 7.6), 1 mM EDTA, 250 mM sucrose]
containing complete protease inhibitor cocktail and PhosSTOP phos-
phatase inhibitor cocktail (Roche Diagnostics, Indianapolis, IN). The
homogenates were centrifuged for 20 min at 9000 rpm at 4 C in a
microfuge, and the supernatants were stored at 80 C. Liver homog-
enates were used in all EMSA experiments except for the determina-
tion of dissociation constants (see below), where nuclear extracts
from transfected and GH-stimulated 293T cells were used. EMSA
analysis of STAT5 binding sites was performed as described previ-
ously (27) with modifications, as detailed in supplemental Materials
and Methods. Oligonucleotides used in EMSA are listed in supple-
mental Table S4.
Dissociation constant for STAT5 binding sites
Kd values were determined by EMSA analysis of STAT5 binding to
oligonucleotides representing sites 224 and 199 of rat SOCS2, sites 296
and 304 of rat IGF-I and sites 8 and 9 of rat OBP3 (see supplemental
Table S4). These assays used nuclear extract (7.5 g protein per EMSA
reaction mixture) prepared from 293T cells transfected with expression
plasmids for rat GH receptor and mouse STAT5b and stimulated with
GH for 30 min. 293T nuclear extracts were prepared using a NucBuster
protein extraction kit (Novagen) and were kindly provided by Dr.
Rosana D. Meyer of this laboratory. A fixed amount of the 32P-labeled
double-stranded probe (0.25 nM) was mixed with an increasing amount
of the same but unlabeled oligonucleotide, up to 100-fold molar excess.
The bands corresponding to STAT5b-bound DNA and free probe were
quantified using ImageQuant software, and Kd values were calculated
by Scatchard plot analysis.
Evaluation of matrices and parameters used for
prediction of STAT5 binding sites
A total of 79 prospective STAT5 binding sites in IGF-I, SOCS2, and
HNF6 were included in the evaluation. These 79 sites include 64 sites for
which real-time PCR primer pairs were designed (primary sites) plus 15
adjacent predicted sites in the rat genome located close enough to the
primary site to be indistinguishable by ChIP. The adjacent sites were
selected as follows. In the case of primary sites that tested negative by
ChIP, the adjacent sites were those located within a 150-bp window
from each end of the amplicon. For primary sites that tested positive (i.e.
showed ChIP enrichment), only those adjacent sites that contained a
consensus STAT5 binding sequence and were identified by STAT5 ma-
trix M00459 were included in the count. The adjacent sites also had to
be located within 300 nt of the end of each amplicon in the case of weak
primary binding sites (sites GHRE-1/GHRE-2, 217, 232, and 260 of
IGF-I and sites 148, 157, and 181 of HNF6) or within 150 nt from the
end of each amplicon in the case of strong binding sites (sites RE-1/RE-2,
263, 296, and 304 of IGF-I and sites 193, 199, 221/222, and 224 of
SOCS2). Each of the 79 sites was classified according to the following 19
possible predictors of binding: presence of a paired STAT5 site; presence
of at least one consensus STAT5 site in rat; presence of at least one
consensus STAT5 site in any species; STAT5 site found in three other
species; STAT5 site found in at least two other species; STAT5 site found
in at least one other species; region of STAT5 site conserved in three
other species; region of STAT5 site conserved in at least two other
species; region of STAT5 site conserved in at least one other species;
STAT5 site that is recognized by each of the nine STAT5 binding site
matrices, with each matrix considered individually; and STAT5 site that
matched any of the matrices with a possum score of at least 7 instead of
the default cutoff score of 5. The 79 tested sites were classified as true
positives (TP), false positives, (FP), true negatives (TN), and false neg-
atives (FN) according to each of the 19 predictors individually, and the
sensitivity [TP/(FN  TP)], specificity [TN/(FP  TN)], PPV [PPV 
TP/(TP  FP)], NPV [NPV  TN/(FN  TN)], and accuracy [(TP 
TN)/(TP  TN  FP  FN)] were calculated for each predictor (sup-
plemental Table S5). The best individual predictors were determined by
plotting sensitivity vs. (1 – specificity) in a receiver operating character-
istic plot (supplemental Fig. S1). The predictors with the best combina-
tion of sensitivity and specificity, i.e. values closest to the (0, 1) point on
the receiver operating characteristic plot, were then identified. The sen-
sitivity, specificity, PPV, NPV, and accuracy were calculated for the
combination of these predictors. To determine the validation rate by
applying the best combination of conditions (consensus site and matrix
459) to sites predicted in four species, three or more species, or two or
more species in IGF-I, SOCS2, and HNF6, STAT5-binding sites were
again predicted in these genes using only matrix 459, and only consensus
sites were chosen. Supplemental Table S6 shows how many of these sites
were tested and how many sites tested positive.
Prediction of STAT5 binding sites in additional early
GH-response genes
Matrix 459 was used to predict STAT5 binding sites in seven
additional GH-responsive rat genes, CALD1, GADD45G, NREP,
SULT2A1, RGS3, SPIN2A, and SPIN2B, and in the MUP gene fam-
ily, using the methods described above for IGF-I, SOCS2, and HNF6.
Sequences comprising 100 kb upstream of the transcription start site,
the full coding sequence region, including all exons and introns, and
25 kb downstream of each coding sequence were scanned for matrix
459 sites, and for all genes except the SPIN2 and MUP genes, rat, mouse,
human, and dog sequences were aligned. In the case of the SPIN2 genes,
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sequences for SPIN2A (NM_012657), SPIN2B (NM_182474), and
SPIN2C (NM_031531) were aligned, with SPIN2B taken as the reference
sequence. Five MUP genes were analyzed: OBP3 (NM_147215), MUP5
(AB039828), MUP4 (NM_198784), LOC259245 (NM_147213), and
LOC259246 (NM_147214), with OBP3 taken as the reference sequence.
These MUP genes are represented by unique hybridization probes and were
similarly regulated by GH in our rat microarray study (52). Sites containing
a STAT5 binding consensus sequence were selected, and the sites were then
classified as paired or single, and as consensus or nonconsensus sites using
all nine STAT5 matrices.
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